Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Taniguchi, S.
Right arrow Articles by Wada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Taniguchi, S.
Right arrow Articles by Wada, M.
Mol Cancer Ther. 2003;2:1351-1359
© 2003 American Association for Cancer Research

Genetic polymorphism at the 5' regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon

Shuichi Taniguchi1, Yasushi Mochida1, Takeshi Uchiumi1, Tomoko Tahira5, Kenshi Hayashi5, Koichi Takagi6, Mitsuo Shimada2, Yoshihiko Maehara2, Hiroyuki Kuwano7, Suminori Kono3, Hitoo Nakano4, Michihiko Kuwano1,8 and Morimasa Wada1

1 Departments of Medical Biochemistry, 2 Surgery and Science, 3 Preventive Medicine, 4 Obstetrics and Gynecology, Graduate School of Medical Science, 5 Division of Genomic Analysis, Research Center for Genomic Information, Kyushu University, Fukuoka, Japan; 6 Coloproctology Center, Takano Hospital, Kumamoto, Japan; 7 Department of Surgery I, Faculty of Medicine, Gunma University, Maebashi, Japan; 8 Research Center for Innovative Cancer Therapy, Kurume, Japan

Requests for Reprints: Morimasa Wada, Department of Medical Biochemistry, Graduate School of Medical Science, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. Phone: 81-92-642-6100; Fax: 81-92-642-6203. E-mail: wada{at}biochem1.med.kyushu-u.ac.jp

The multidrug resistance 1 (MDR1) is a key molecule in determining not only the resistance of cancer cells to anticancer agents but also the disposition of a variety of drugs in intestinal and other tissues. However, the mechanism underlying interindividual variations in levels of MDR1 activity and expression in various tissues remains unclear. We analyzed the nucleotide sequence polymorphisms in the 5' upstream regulatory region of the gene spanning 4 kb from the transcriptional start site of MDR1 and tried to identify any associations between polymorphisms and MDR1 expression. Within that region, we identified eight single nucleotide polymorphisms (SNPs) in the region in the Japanese population. Of the SNPs identified, -2410T>C, -1910T>C, and 692T>C were in perfect linkage disequilibrium. In normal colorectal mucosa, diplotypes at the region showed more significant association with the expression level of MDR1 mRNA than each SNP did. In an in vitro reporter assay, transcription activity of the minor-type construct carrying haplotypes 2 and 3 was significantly lower than that of the major-type construct carrying haplotype 1. We next identified two DNA binding proteins: one protein bound to the nucleotide sequence carrying -692T but not to that carrying -692C and another bound to the nucleotide sequence carrying -2352G but three times weaker than that carrying -2352A. This suggested the significance of SNP at -692 and -2352 of MDR1 in variable expression in the colon interindividually. This is the first report connecting SNPs and interindividual variety of MDR1 expression rationally.


The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Grant support: Grant-in-Aid for Cancer Research, Scientific Research on Priority Areas (C) "Medical Genome Science" and Scientific Research on Priority Areas (B) "Biological Transport Nano-Machine: Structure, Function, and Regulation" from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

Received 6/ 6/03; revised 9/22/03; accepted 10/ 1/03.




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
K. Ogasawara, T. Terada, J.-i. Asaka, T. Katsura, and K.-i. Inui
Human Organic Anion Transporter 3 Gene Is Regulated Constitutively and Inducibly via a cAMP-Response Element
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 317 - 322.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
B. Wang, S. Ngoi, J. Wang, S. S. Chong, and C. G. L. Lee
The Promoter Region of the MDR1 Gene Is Largely Invariant, but Different Single Nucleotide Polymorphism Haplotypes Affect MDR1 Promoter Activity Differently in Different Cell Lines
Mol. Pharmacol., July 1, 2006; 70(1): 267 - 276.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
S. Labialle, G. Dayan, L. Gayet, D. Rigal, J. Gambrelle, and L. G. Baggetto
New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein
Nucleic Acids Res., July 22, 2004; 32(13): 3864 - 3876.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.